Skip to main content

Table 3 Clinical characteristics of the patients before and after BT

From: Bronchial thermoplasty in severe asthma: a real-world study on efficacy and gene profiling

Parameter T0 T12 p-value
No. of patients 27 27 _
Total serum IgE KU/l, median [IQR] 65 [30–160] 87 [27–272] 0.2552
Blood eosinophil count cells/µl, median [IQR] 140 [20–410] 340 [120–640] 0.1533
Lung function, pre-bronchodilator
FEV1%,median [IQR] 71 [63–94] 67 [59–87] 0.0179
 FEV1 l, median [IQR] 2.43 [1.86–3.22] 1.97 [1.5–2.68] 0.0103
 FVC %, median [IQR] 99 [89–114] 86 [77–102] 0.0011
 FVC l, median [IQR] 3.62 [2.90–4.62] 3.19 [2.57–3.89] 0.0051
Asthma concomitant medication
 Oral corticosteroid-prednisone or the equivalent mg, median [IQR] 20 [5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25] 5 [0–12.5]  < 0.0001
 Patients taking OCS, n (%) 24 (89) 15 (55) 0.0058
 Patients taking LAMA, n (%) 12 (44) 21 (77) 0.0244
 Patients taking LTRA, n (%) 10 (37) 6 (22) 1
 Patients taking theophylline, n (%) 4 (15) 0 (0) 0.1110
Assigned adapted GINA* step
 Step 4, n (%) 2 (7) 3 (11) 1
 Step 5, n (%) 25 (93) 24 (89) 1
Asthma control
 Exacerbations/y, median [IQR] 6 [3,4,5,6,7,8,9,10] 2 [1,2,3]  < 0.0001
 ED visits/hospitalizations/y, median [IQR] 0 [0–1] 0 [0–0] 0.0022
Patient reported outcomes
 AQLQ score, median [IQR] 2.6 [2.1–3.0] 5.5 [4.4–6.0]  < 0.0001
 ACQ score, median [IQR] 3.8 [3.2–4.6] 1.6 [1.2–2.0]  < 0.0001
  1. *GINA 2019 asthma guidelines
  2. Data were compared with Mann Withney U test (continuous variables) and Fisher exact test (categorical variables)
  3. P < 0.05 were considered statistically significant. IQR interquartile range